Continuous inhibition of excessive polyol pathway flux in peripheral nerves by aldose reductase inhibitor fidarestat leads to Improvement of diabetic neuropathy

Journal of Diabetes and its Complications

Volumn 13, Issue 3, 1999, Pages 141-150

  Mizuno, Kuniharu ^a   Kato, Noriaki ^a   Makino, Mitsuhiro ^a   Suzuki, Tsunemasa ^a   Shindo, Masaomi ^b  

^a Pharmaceutical Laboratory   (Japan)

^b SHINSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSE REDUCTASE INHIBITOR; EPALRESTAT; FIDARESTAT; GLYCOSYLATED HEMOGLOBIN; POLYOL; SORBITOL; ZENARESTAT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIABETIC NEUROPATHY; GLUCOSE BLOOD LEVEL; MALE; MOTOR NERVE CONDUCTION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SCIATIC NERVE; SENSORY NERVE CONDUCTION; STREPTOZOCIN DIABETES;

EID: 0032843080     PISSN: 10568727     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1056-8727(99)00038-0     Document Type: Article

References (69)

1. Kador P.F., Robison W.G. Jr., Kinoshita J.H. The pharmacology of aldose reductase inhibitors. Ann Rev Pharmacol Toxicol. 25:1985;691-714.
2. Gabbay K.H. Role of sorbitol pathway in neuropathy. Camerini-Davalos R.A., Cole H.S. Vascular and Neurological Changes in Early Diabetes. 1973;417-424 Academic, New York.
3. Gabbay K.H. Hyperglycemia, polyol metabolism, and complications of diabetes mellitus. Ann Rev Med. 26:1975;521-536.
4. Kinoshita J.H. Mechanisms initiating cataract formation. Invest Ophthalmol. 13:1974;713-724.
5. Robison W.G. Jr., McCaleb M.L., Feld L.G., Michaelis O.E. 4th, Laver N., Mercandetti M. Degenerated intramural pericytes ('ghost cells') in the retinal capillaries of diabetic rats. Curr Eye Res. 10:1991;339-350.
6. Akita M., Mizuno K., Matsubara A., Nakano K., Kurono M. Effects of an aldose reductase inhibitor, SNK-860, on the histopathological changes of retinal tissues in a streptozotocin-induced diabetic rat model. Acta Medica Okayama. 47:1993;299-304.
7. MacCaleb M.L., Sredy J., Millen J., Ackerman D.M., Dvornik D. Prevention of urinary albumin excretion in 6 month streptozotocin-diabetic rats with the aldose reductase inhibitor tolrestat. J Diabet Complications. 2:1988;16-18.
8. Kikkawa R., Umemura K., Haneda M., Arimura T., Ebata K., Shigeta Y. Evidence for existence of polyol pathway in cultured rat mesangial cells. Diabetes. 36:1987;240-243.
9. Raskin P., Rosenstock J. Aldose reductase inhibitors and diabetic complications. Am J Med. 83:1987;298-306.
10. Clements R.S. Jr. Diabetic neuropathy - New concepts of its etiology. Diabetes. 28:1979;604-611.
11. Judzewitch R.G., Jaspan J.B., Polonsky K.S., Weinberg C.R., Halter J.B., Halar E., Pfeifer M.A., Vukadinovic C., Bernstein L., Schneider M., Liang K.Y., Gabbay K.H., Rubenstein A.H., Porte D. Jr. Aldose reductase inhibition improves nerve conduction velocity in diabetic patients. N Engl J Med. 308:1983;119-125.
12. Stribling D., Armstrong F.M., Perkins C.M., Smith J.C. Aldose reductase in the ethiology of diabetic complications. Neuropathy. J Diabet Complications. 3:1989;139-148.
13. Greene D.A., Sima A.A., Stevens M.L., Feldman E.L., Lattimar S.A. Complications. neuropathy, pathogenetic considerations Diabetes Care. 15:1992;1902-1925.
14. Santiago J.V., Sönksen P.H., Boulton A.J.M., Macleod A., Beg M., Bochenek W., Graepel G.J., Gonen B., the Tolrestat Study Group Withdrawal of the aldose reductase inhibitor tolrestat in patients with diabetic neuropathy. Effect on nerve function J Diabet Complications. 7:1993;170-178.
15. Gabbay K.H., Snider J.J. Nerve conduction defect in galactose-fed rats. Diabetes. 21:1972;295-300.
16. Jakobsen J. Peripheral nerves in early experimental diabetes. Expansion of the endoneurial space as a cause of increased water content Diabetologia. 14:1978;113-119.
17. Stevens M.J., Lattimer S.A., Kamijo M., Van Huysen C., Sima A.A.F., Greene D.A. Osmotically-induced nerve taurine depletion and the compatible osmolyte hypothesis in experimental diabetic neuropathy in the rat. Diabetologia. 36:1993;608-614.
18. Stewart M.A., Kurien M.M., Sherman W.R., Cotlier E.V. Inositol changes in nerve and lens of galactose fed rats. J Neurochem. 15:1968;941-946.
19. Greene D.A. A sodium-pump defect in diabetic peripheral nerve corrected by sorbinil administration. Relationship to myo-inositol metabolism and nerve conduction slowing Metabolism. 35(suppl 1):1986;60-65.
20. Brownlee M. Glycation products and the pathogenesis of diabetic complications. Diabetes Care. 15:1992;1835-1843.
21. Tilton R.G., Chang K., Nyengaard J.R., Van den Enden M., Ido Y., Williamson J.R. Inhibition of sorbitol dehydrogenase. effects on vascular and neural dysfunction in streptozotocin-induced diabetic rats Diabetes. 44:1995;234-242.
22. Cameron N.E., Cotter M.A. Metabolic and vascular factors in the pathogenesis of diabetic neuropathy. Diabetes. 46(suppl 2):1997;S31-S37.
23. Hotta N. New concepts and insights on pathogenesis and treatment of diabetic complications. Polyol pathway and its inhibition Nagoya J Med Sci. 60:1997;89-100.
24. Gabbay K.H., Merola L.O., Field R.A. The sorbitol pathway. Presence in nerve and cord with substrate accumulation in diabetes Science. 151:1966;209-210.
25. Stewart M.A., Sherman W.R., Anthony S. Free sugars in alloxan diabetic rat nerve. Biochem Biophys Res Commun. 22:1966;488-491.
26. Gabbay K.H., O'Sullivan J.B. The sorbitol pathway. Enzyme localization and content in normal and diabetic nerve cord Diabetes. 17:1968;239-243.
27. +-ATPase activity Metabolism. 39:1990;563-567.
28. Mayer J.H., Tomlinson D.R. Prevention of defects of axonal transport and nerve conduction velocity by oral administration of myo-inositol or an aldose reductase inhibitor in streptozotocin-diabetic rats. Diabetologia. 25:1983;433-438.
29. Finegold D., Lattimer S.A., Nolle S., Bernstein M., Greene D.A. Polyol pathway activity and myo-inositol metabolism. A suggested relationship in the pathogenesis of diabetic neuropathy Diabetes. 32:1983;988-992.
30. Hamada Y., Araki N., Horiuchi S., Hotta N. Role of polyol pathway in nonenzymatic glycation. Nephrol Dial Transplant. 11(suppl 5):1996;95-98.
31. Cameron N.E., Cotter M.A., Hohman T.C. Interactions between essential fatty acid, prostanoid, polyol pathway and nitric oxide mechanisms in the neurovascular deficit of diabetic rats. Diabetologia. 39:1996;172-182.
32. Mizuno K., Kato N., Matsubara A., Nakano K., Kurono M. Effects of a new aldose reductase inhibitor, (2S, 4S)-6-fluoro-2′, 5′-dioxospiro[chroman-4, 4′-imidazolidine]-2-carboxamide (SNK-860), on the slowing of motor nerve conduction velocity and metabolic abnormalities in the peripheral nerve in acute streptozotocin-induced diabetic rats. Metabolism. 41:1992;1081-1086.
33. Kador P.F. Aldose reductase inhibitors. Sakamoto N., Kinoshita J.H., Kador P.F., Hotta N. Current Concepts of Aldose Reductase and Its Inhibitions. 1990;73-80 Elsevier, Amsterdam.
34. Hatta N., Sakamoto N., Shigeta Y., Kikkawa R., Goto Y., the Diabetic Neuropathy Study Group in Japan Clinical investigation of epalrestat, an aldose reductase inhibitor, on diabetic neuropathy in Japan. Multicenter study J Diabet Complications. 10:1996;168-172.
35. Greene D.A., Arezzo J., Brown M., the Zenaredtat Study Group Dose-related effects of aldose reductase inhibitor Zenarestat on nerve sorbitol levels, nerve conduction velocity and nerve fiber density in human diabetic neuropathy (Abstract). Diabetes. 45(suppl 2):1996;5A.
36. Kato N., Makino M., Mizuno K., Suzuki T., Shindo M. Serial changes of sensory nerve conduction velocity and minimal F-wave latency in streptozotocin-induced diabetic rats. Neurosci Lett. 244:1998;169-172.
37. Miyoshi T., Goto I. Serial in vivo determinations of nerve condition velocity in rat tails. Physiological and pathological changes. Electroencephalogr Clin Neurophysiol. 35:1973;125-131.
38. Wiethölter H., Hülser P.J., Linington C., Meier D.H., Wessel K. Electrophysiological follow up of experimental allergic neuritis mediated by a permanent T cell line in rats. J Neurol Sci. 83:1988;1-14.
39. Abraham E.C., Perry R.E., Stallings M. Application of affinity chromatography for separation and quantitation of glycosylated hemoglobins. J Lab Clin Med. 102:1983;187-197.
40. Cameron N.E., Cotter M.A., Robertson S. The effect of aldose reductase inhibition on the pattern of nerve conduction deficits in diabetic rats. Q J Exp Physiol. 74:1989;917-926.
41. Ao S., Shingu Y., Kikuchi C., Takano Y., Nomura K., Fujiwara T., Ohkubo Y., Notsu Y., Yamaguchi I. Characterization of a novel aldose reductase inhibitor, FR74366, and its effects on diabetic cataract and neuropathy in the rat. Metabolism. 40:1991;77-87.
42. Yoshida M., Sugiyama Y., Akaike N., Ashizawa N., Aotsuka T., Ohbayashi S., Matsuura A. Amelioration of neurovascular deficits in diabetic rats by a novel aldose reductase inhibitor, GP-1447. Minor contribution of nitric oxide Diabetes Res Clin Pract. 40:1998;101-112.
43. Nakamura J., Koh N., Sakakibara F., Hamada Y., Wakao T., Sasaki H., Mori K., Nakashima E., Naruse K., Hotta N. Diabetic neuropathy in sucrose-fed Otsuka Long-Evans Tokushima fatty rats. Effect of an aldose reductase inhibitor, TAT Life Sci. 60:1997;1847-1857.
44. Kato N., Mizuno K., Matsubara A., Nakano K., Kurono M., Yagihashi S. Effect of long-term treatment with a new aldose reductase inhibitor, (2S,4S)-6-fluoro-2′,5′-dioxospiro[chroman - 4,4′ - imidazolidine] - 2 - carboxamide(SNK-860), on peripheral neuropathy in streptozotocin-induced diabetic rats. J Diabet Complications. 8:1994;27-32.
45. 1 analogue, OP1206.αCD, completely improves sciatic motor nerve conduction velocity in streptozotocin-induced chronically diabetic rats. Metabolism. 41:1992;778-782.
46. Carrington A.L., Ettinger C.B., Tomlinson D.R. Increased resistance to hypoxic conduction block in sciatic nerves of diabetic rats. Effects of extracellular glucose concentration and of aldose reductase inhibition J Diabet Complications. 8:1994;33-39.
47. Miwa I., Hirano M., Kanbara M., Okuda J. In vivo activities of aldose reductase inhibitors having a 1-(arylsulfonyl)hydantoin structure. Biochem Pharmacol. 40:1990;303-307.
48. Julu P.O.O. The correlation between sensory nerve conduction velocities and three metabolic indices in rats treated with streptozotocin. Diabetologia. 31:1988;247-253.
49. Stanley E.F. Sensory and motor nerve conduction velocities and the latency of the H reflex during growth of the rat. Exp Neurol. 71:1981;497-506.
50. 2+ antagonist, nimodipine of an existing neuropathy in the streptozotocin-induced diabetic rat. Br J Pharmacol. 108:1993;780-785.
51. Das P.K., Bray G.M., Aguayo A.J., Rasminsky M. Diminished ouabain-sensitive, sodium-potasium ATPase activity in sciatic nerves of rats with streptozotocin-induced diabetes. Exp Neurol. 53:1976;285-288.
52. Brismar T. Neuropathy-functional abnormalities in the BB rat. Metabolism. 32(suppl 1):1983;112-117.
53. Brismar T., Sima A.A.F., Greene D.A. Reversible and irreversible nodal dysfunction in diabetic neuropathy. Ann Neurol. 21:1987;504-507.
54. Stevens M.J., Dananberg J., Feldman E.L., Lattimer S.A., Kamijo M., Thomas T.P., Shindo H., Sima A.A.F., Greene D.A. The linked roles of nitric oxide, aldose reductase and, (Na+,K+)-ATPase in the slowing of nerve conduction in the streptozotocin diabetic rat. J Clin Invest. 94:1994;853-859.
55. Andersen H., Stålberg E., Falck B. F-wave latency, the most sensitive nerve condition parameter in patients with diabetes mellitus. Muscle Nerve. 20:1997;1296-1302.
56. Panayiotopoulos C.P., Scarpalezos S., Nastas P.E. Sensory (1a) and F-wave conduction velocity in the proximal segment of the tibial nerve. Muscle Nerve. 1:1978;181-189.
57. Terada M. Electrophysiological studies of dorsal column dysfunction in experimental diabetic and 2, 5-hexanedione neuropathy rats. J Japan Diab Soc. 31:1988;223-230.
58. Yoshida T., Nishioka H., Yashioka K., Nakano K., Kondo M., Terashima H. Effect of aldose reductase inhibitor ONO 2235 on reduced sympathetic nervous system activity and peripheral nerve disorders in STZ-induced diabetic rats. Diabetes. 36:1987;6-13.
59. 1 analogue TFC 612 on diabetic neuropathy in streptozotocin-induced diabetic rats. Comparison with aldose reductase inhibitor ONO 2235. Diabetes. 38:1989;832-838.
60. Terashima H., Hama K., Yamamoto R., Tsuboshima M., Kikkawa R., Hatanaka I., Shigeta Y. Effects of a new aldose reductase inhibitor on various tissues in vitro. J Pharmacol Exp Ther. 229:1983;226-230.
61. Inukai S., Agata M., Sato M., Naitou A., Matsukawa H., Goto M. Characterization of a novel aldose reductase inhibitor, TAT and its effect on streptozotocin-induced diabetic neuropathy in rats. Jpn J Pharmacol. 61:1993;221-227.
62. Sawada M., Terashima H., Okegawa T., Kawasaki A. Pharmacokinetic study of epalrestat (ONO 2235). Sakamoto N., Kinoshita J.H., Kador P.F., Hotta N. Current Concepts of Aldose Reductase and Its Inhibitions. 1990;111-118 Elsevier, Amsterdam.
63. Horie S., Nagai H., Yuuki T., Narita Y., Tsuda Y., Nakajima T., Nakamura N. Effect of SG-210, a novel aldose reductase inhibitor, on impaired polyol pathway in rats received diabetic manipulations. J Diabet Complications. 12:1998;163-169.
64. Tomlinson D.R., Moriarty R.J., Mayer J.H. Prevention and reversal of defective axonal transport and motor nerve conduction velocity in rats with experimental diabetes by treatment with the aldose reductase inhibitor Sorbinil. Diabetes. 33:1984;470-476.
65. Greene D.A., Chakrabarti S., Lattimer S.A., Sima A.A.F. Role of sorbitol accumulation and myo-inositol depletion in paranodal swelling of large myelinated nerve fibers in the insulin-deficient spontaneously diabetic bio-breeding rat. Reversal by insulin replacement, an aldose reductase inhibitor, and myo-inositol. J Clin Invest. 79:1987;1479-1485.
66. Young R.J., Ewing D.J., Clarke B.F. A controlled trial of sorbinil, an aldose reductase inhibitor, in chronic painful diabetic neuropathy. Diabetes. 32:1983;938-942.
67. Sima A.A.F., Bril V., Nathaniel V., McEwen T.A., Brown M.B., Lattimer S.A., Greene D.A. Regeneration and repair of myelinated fibers in sural-nerve biopsy specimens from patients with diabetic neuropathy treated with sorbinil. N Engl J Med. 319:1988;548-555.
68. Sima A.A.F., Prashar A., Nathaniel V., Bril V., Werb M.R., Greene D.A. Overt diabetic neuropathy. Repair of axo-glial dysjunction and axonal atrophy by aldose reductase inhibition and its correlation to improvement in nerve conduction velocity Diabetic Med. 10:1993;115-121.
69. Jaspan J.B., Towle V.L., Maselli R., Herold K. Clinical studies with an aldose reductase inhibitor in the autonomic and somatic neuropathies of diabetes. Metabolism. 35(suppl 1):1986;83-92.